Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide

Oncolytic herpes simplex virus (oHSV) mutants are under development as anticancer therapeutics. One such vector, rRp450, is ICP6-deleted and expresses a prodrug enzyme for cyclophosphamide (CPA) (rat CYP2B1). Little is known about rRp450’s toxicity profile, especially in combination with CPA. We tes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Currier, Mark A, Gillespie, Rebecca A, Sawtell, Nancy M, Mahller, Yonatan Y, Stroup, Greg, Collins, Margaret H, Kambara, Hirokazu, Chiocca, E Antonio, Cripe, Timothy P
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860295/
https://ncbi.nlm.nih.gov/pubmed/18388918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2008.49
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados